immune thrombocytopenia
Conditions
Interventions
Observation group:None
Sponsors
Beijing Childrens Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 1–18 years. 2. Meets diagnostic criteria outlined in the Revised Chinese Guidelines for Diagnosis and Treatment of Primary Immunological Thrombocytopenia in Children (2021 Edition). 3. Has received treatment with at least one TPO receptor antagonist (e.g., eltrombopag, roux-Vorspin, avatrombopag). 4. Completed bone marrow biopsy following initiation of TPO-RA therapy, with a comprehensive pathological report including reticulin fibre staining (Gomori silver staining) and fibrosis grading.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with secondary ITP (e.g., secondary to systemic lupus erythematosus, Evans syndrome, etc.) or coexisting with other clearly defined haematological disorders (e.g., myelodysplastic syndromes, hereditary thrombocytopenia, etc.). 2. Critical information is missing from clinical case records or bone marrow pathology data, rendering effective grouping or analysis impossible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall incidence of myelofibrosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Distribution proportions of different fibrosis grades (MF-0, MF-1, MF-2/3);Differences in serum TPO levels between groups;Inter-group TPO-RA usage characteristics;Among children who discontinued treatment, the proportion experiencing a reduction or reversal in the grade of bone marrow fibrosis; | — |
Countries
China
Contacts
Public ContactJingyao Ma
Beijing Childrens Hospital,Capital Medical University
Outcome results
None listed